Why Valneva’s Ixiaro quietly sets the standard for travel vaccines

A small syringe, a big promise: with Ixiaro, Valneva targets travelers heading into tick-heavy regions of Asia and Europe who want protection from Japanese encephalitis without dragging a complicated schedule into their trip planning.

Reviewed: ad hoc news Software & Services desk. Edited and checked on 2026-06-18, 02:56. Details in the imprint.

With Ixiaro, Valneva’s travel vaccine for Japanese encephalitis, the consultation room suddenly feels a bit more relaxed than the mosquito-plagued rice fields it prepares you for. Two shots, a clear schedule, and a virus that most travelers never even want to hear pronounce.

What Ixiaro is designed to do

Ixiaro is a purified, inactivated vaccine that targets Japanese encephalitis, a viral brain infection transmitted by mosquitoes in parts of Asia and the Western Pacific. It is designed for adults and children from 2 months of age who travel or live in endemic areas.

The formulation uses an inactivated SA14-14-2 virus strain grown on cell culture, then purified and adjuvanted with aluminum to trigger a strong immune response. Unlike live vaccines, it cannot replicate in the body, which tends to reassure cautious travelers and risk-conscious physicians.

Dosing schedule and everyday practicality

The standard Ixiaro schedule consists of two intramuscular injections, typically given on day 0 and day 28, with the second dose at least one week before potential exposure. That “two visits, one month” rhythm fits reasonably well into pre-trip planning for longer journeys.

For adults aged 18 to 65 years, regulators have approved an accelerated schedule on day 0 and day 7 when time is tight, as long as the second dose still precedes exposure by at least a week. Travelers who prepare late can therefore still leave the consultation room with convincing protection prospects.

Protection levels and how long they last

In clinical trials, more than 96 percent of adult participants developed protective neutralizing antibody titers 28 days after the second Ixiaro dose. That high seroconversion rate has made the product a reference point in travel medicine guidelines.

Antibody levels decline over time, which is why booster doses are recommended for ongoing risk. In adults, a booster is advised within 12 to 24 months after the primary series if exposure continues or recurs. For many holidaymakers, that means only a booster before the next big Asia trip.

Side effects and tolerability profile

Typical Ixiaro reactions are local pain, tenderness, or redness at the injection site along with transient headache or muscle pain. Most events are mild to moderate and resolve within a few days, which matches the expectations of seasoned travel clinic staff.

Serious adverse events related to the vaccine have been rare in studies and post-marketing surveillance. As with all vaccines, anaphylaxis is a theoretical risk, so healthcare providers remain equipped for emergencies, but for everyday practice Ixiaro is seen as a largely quiet companion.

Where it fits in the travel portfolio

Japanese encephalitis may be rare among short-stay city tourists, but the risk climbs for backpackers, long-term travelers, and expatriates who spend time in rural or agricultural areas. For exactly these groups, Ixiaro often appears as a firm line item on the checklist.

Valneva positions the vaccine alongside its broader travel portfolio, which includes products against cholera and other pathogens. The mix helps clinics offer a compact set of branded solutions instead of juggling a patchwork of less specialized options.

Availability and price signals

Ixiaro is licensed in the European Union, the United Kingdom, the United States, Canada, Australia, and several Asian markets, usually under prescription via travel clinics or hospital vaccination centers. In Germany, specialized travel medicine practices often stock it as a standard option for Asia-bound travelers.

List prices vary by country and reimbursement system. In many European markets, the vaccine sits in the mid to upper two-digit euro range per dose for private payers, while public or employer plans sometimes cover at least part of the cost when travel is job-related.

Context for Valneva and its listing

Ixiaro has been one of Valneva’s most important revenue drivers in recent years, anchoring its positioning as a specialist in travel and emerging disease vaccines. The product’s stable demand contrasts with the more volatile attention around pipeline projects such as Lyme disease and chikungunya candidates.

Shares of Valneva SE (FR0013280286) trade in Paris and on Nasdaq, giving the mid-cap vaccine developer access to both European and US capital markets for funding its clinical programs.

Key facts about Ixiaro at a glance

• Product: Ixiaro
• Manufacturer: Valneva SE
• Category: Travel vaccine (Japanese encephalitis)
• Launch: Initially approved in the EU in 2009, later in the US
• RRP / Price: Typically mid to upper two-digit range per dose (local currency, varies by market)
• Availability: Prescription through travel clinics, hospitals, and specialized vaccination centers in the EU, US, and other licensed markets
• Target group: Travelers, expatriates, and military personnel heading to Japanese encephalitis endemic areas
• Highlight / USP: Inactivated, purified vaccine with a compact two-dose schedule and high seroconversion rates in adults

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.